论文部分内容阅读
目的观察大剂量促红素冲击治疗癌症贫血的临床疗效及毒副反应。方法将82例癌症贫血患者随机分为常规剂量组(促红素1万U,每周3次,共6周)与大剂量组(促红素4万U/次,d1、d3、d6、d9、d12、d15),共观察6周,每2周进行1次疗效评价。观察两组患者的有效率、血红蛋白值、输血需求率、停药者比率及药物的不良反应,每2周进行1次疗效评价。结果常规剂量组4周后血红蛋白明显升高,大剂量组治疗2周后血红蛋白明显升高;大剂量组的4周、6周血红蛋白值均高于常规剂量组(P<0.05);大剂量组的2周、4周、6周有效率分别为39.0%、53.6%、75.6%,高于常规剂量组的17.5%、32.5%、50.0%(P<0.05);两组输血需求率及不良反应发生率差异无统计学意义(P>0.05)。结论大剂量促红素冲击治疗癌症贫血的疗效优于常规剂量法,毒副反应无明显增加。
Objective To observe the clinical efficacy and side effects of high dose erythropoietin in the treatment of cancer anemia. Methods Eighty-two patients with cancer anemia were randomly divided into routine dose group (erythropoietin 10,000 U, three times a week for 6 weeks) and high dose group (erythropoietin 40,000 U / time, d1, d3, d6, d9, d12, d15) were observed for 6 weeks, once every 2 weeks for efficacy evaluation. Observe the efficiency of the two groups of patients, hemoglobin value, blood transfusion requirements, the ratio of drug withdrawal and adverse drug reactions, once every 2 weeks to evaluate the efficacy. Results After 4 weeks, the hemoglobin of the normal dose group was significantly increased, and the hemoglobin of the high dose group was significantly increased after 2 weeks of treatment. The hemoglobin values of the high dose group were higher than those of the conventional dose group at 4 weeks and 6 weeks (P <0.05) (P <0.05). The effective rates of two weeks, four weeks and six weeks were 39.0%, 53.6% and 75.6% respectively, higher than those of the conventional dose group (17.5%, 32.5% and 50.0% The difference was not statistically significant (P> 0.05). Conclusion The effect of high-dose erythropoietin treatment on cancer anemia is superior to that of conventional dose method with no obvious increase of toxic and side effects.